Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG005 + bevacizumab versus sintilimab + bevacizumab as first-line treatment for advanced hepatocellular carcinoma
CTR20263448Phase 3Active
- Sponsor
- Zelgen
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nilvanstomig, bevacizumab, sintilimab in hepatocellular carcinoma (HCC), sponsored by Zelgen. Started Sep 2026; status: active.
02
Drugs
nilvanstomigbevacizumabsintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20263448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263448.